149 related articles for article (PubMed ID: 38167641)
1. ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer.
Luo Y; Li Q; Fang J; Pan C; Zhang L; Xu X; Qian S; Zhao X; Hou L
Sci Rep; 2024 Jan; 14(1):197. PubMed ID: 38167641
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy.
Dou H; Li F; Wang Y; Chen X; Yu P; Jia S; Ba Y; Luo D; Gao T; Li Z; Xiao M
Diagn Pathol; 2024 Jan; 19(1):5. PubMed ID: 38178166
[TBL] [Abstract][Full Text] [Related]
3. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
Wei JL; Zhang JX; Fu DY
World J Surg Oncol; 2018 Dec; 16(1):236. PubMed ID: 30558615
[TBL] [Abstract][Full Text] [Related]
4. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
5. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
Breast J; 2022; 2022():9238804. PubMed ID: 35711896
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
7. Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype.
Mao J; Hu J; Zhang Y; Shen J; Dong F; Zhang X; Ming J; Huang T; Run X
Front Endocrinol (Lausanne); 2021; 12():628939. PubMed ID: 33972826
[TBL] [Abstract][Full Text] [Related]
8. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.
Li J; Gonzalez-Angulo AM; Allen PK; Yu TK; Woodward WA; Ueno NT; Lucci A; Krishnamurthy S; Gong Y; Bondy ML; Yang W; Willey JS; Cristofanilli M; Valero V; Buchholz TA
Oncologist; 2011; 16(12):1675-83. PubMed ID: 22147002
[TBL] [Abstract][Full Text] [Related]
10. Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.
Schinkel JK; Zahm SH; Jatoi I; McGlynn KA; Gallagher C; Schairer C; Shriver CD; Zhu K
Cancer Causes Control; 2014 Aug; 25(8):959-68. PubMed ID: 24839049
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features of inflammatory versus noninflammatory locally advanced nonmetastatic breast cancer.
Brouwers B; Paridaens R; Lobelle JP; Hendrickx W; Smeets A; Neven P; Weltens C; Deraedt K; Vanden Bempt I; Christiaens MR; Wildiers H
Tumour Biol; 2008; 29(4):211-6. PubMed ID: 18781092
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR-/HER2+ breast cancer subtypes.
Ding W; Ye D; Chen H; Lin Y; Li Z; Tu C
Breast Cancer; 2024 Mar; 31(2):295-304. PubMed ID: 38231460
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
[TBL] [Abstract][Full Text] [Related]
14. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
16. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
[TBL] [Abstract][Full Text] [Related]
19. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
20. ER-/PR+ subset of invasive breast carcinoma (IBC): a distinct phenotype with good prognosis.
Stolnicu S; Bauer O; Naznean A; Podoleanu C; Georgescu R
Pol J Pathol; 2018; 69(3):311-313. PubMed ID: 30509058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]